[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Cryptosporidiosis Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

October 2019 | 40 pages | ID: C20D00E237CFEN
VPAResearch

US$ 1,699.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Cryptosporidiosis Drug pipeline report- 2020 is an annual R&D review of Cryptosporidiosis pipeline candidates. The report presents the current status of all major Cryptosporidiosis therapeutic compounds. Detailed insights into Cryptosporidiosis pipeline development, current status, companies, drug profiles and Cryptosporidiosis preclinical and clinical trials are included.

2020 Cryptosporidiosis Pipeline Market Insights
Cryptosporidiosis disease overview, 2020 pipeline review, insights into leading companies, dominant mechanism of action, majority of administration route of Cryptosporidiosis therapies, pipeline by phase and others are included.

Cryptosporidiosis pipeline Drug profiles-
Active and inactive drug profiles covering information including drug name/synonym, sponsor/collaborators/Developer/originator, drug mechanism, route of administration, orphan drug status, NME, phase, development status, and others are included.

Cryptosporidiosis Therapeutic Drug candidates
Both active and inactive Cryptosporidiosis pipeline drug candidates are included in the report

Cryptosporidiosis Clinical Trials and preclinical Studies
Cryptosporidiosis In-vitro and In-vivo studies, discovery stage and pre-clinical stage trial details, Clinical trial titles, duration, location, phase, sponsors, and other details are provided.

Cryptosporidiosis pipeline market developments
Cryptosporidiosis Pipeline market news and deals including mergers, acquisitions, approvals, collaborations, trial initiations, results, investments, licensing opportunities and others are provided.

Cryptosporidiosis pipeline companies in active development
The report analyzes Cryptosporidiosis pipeline of the below companies-

AbbVie Inc, ioGenetics Inc, Novartis AG, Romark Laboratories

Report Coverage

What to look out for in 2020
Drugs moving from early stage to mid-to-late stages and drugs to look after in 2020 are included

Pipeline Snapshot
Pipeline candidate count - Drug by phase, mechanism of action, route of administration, designation and others

Companies
4 Companies investing in Cryptosporidiosis pipeline from discovery stage to pre-registration phase are included

Drug profiles
Over 10 details of each Cryptosporidiosis pipeline candidate are included

Company Profiles
Business overview and contact details of all companies operating in the industry are provided

Market Developments
News, Developments and other recent industry developments are included
1. CRYPTOSPORIDIOSIS PIPELINE MARKET INSIGHTS, 2020

1.1 Cryptosporidiosis Disease Overview
1.2 Cryptosporidiosis Drug Pipeline Snapshot, 2020
  1.2.1 Cryptosporidiosis Pipeline Drugs by Phase
  1.2.2 Cryptosporidiosis Pipeline Drugs by Company
  1.2.3 Cryptosporidiosis Pipeline Drugs by Mechanism of Action
  1.2.4 Cryptosporidiosis Pipeline Drugs by Route of Administration

2. CRYPTOSPORIDIOSIS COMPANY WISE PIPELINE DETAILS

AbbVie Inc Cryptosporidiosis Pipeline Drugs
  Company Profile
  Drug Candidate Details
ioGenetics Inc Cryptosporidiosis Pipeline Drugs
  Company Profile
  Drug Candidate Details
Novartis AG Cryptosporidiosis Pipeline Drugs
  Company Profile
  Drug Candidate Details
Romark Laboratories Cryptosporidiosis Pipeline Drugs
  Company Profile
  Drug Candidate Details

3. CRYPTOSPORIDIOSIS DRUG PIPELINE PROFILES

3.1 Discovery and Preclinical Drug Profiles
3.2 Phase 1 Drug Profiles
3.3 Phase 2 Drug Profiles
3.4 Phase 3 Drug Profiles

4. CRYPTOSPORIDIOSIS PIPELINE NEWS AND DEVELOPMENTS

5. APPENDIX

5.1 Primary and Secondary Research Methodology
5.2 Publisher Expertize
5.3 Contacts


More Publications